821/1507US=39 / Câncer
Gambari R. Targeting transcription factors with decoy oligonucleotideos: modulation of the expression of genes involved in chemotherapy resistance of tumor cells. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 175-87. ISBN 978-1-58829-989-5.

FATORES DE TRANSCRICAO; OLIGONUCLEOTIDEOS DE ENGODO; MODULACAO DA EXPRESSAO DE GENES; RESISTENCIA A QUIMIOTERAPIA; CELULAS TUMORAIS


822/1507US=39 / Câncer
Maina F, Dono R. p53 inhibitors as cancer sensitizing agents. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 189-202. ISBN 978-1-58829-989-5.

INIBIDORES P53; SENSIBILIZACAO DO CANCRO


823/1507US=39 / Câncer
Bonavida B, Huerta-Yepez S, Vega MI, Spandidos DA, Baritaki S. Nitric oxide-induced immunosensitization to apoptosis by Fas-L and TRAIL. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 203-10. ISBN 978-1-58829-989-5.

IMMUNOSENSIBILIZACAO; OXIDO NITRICO; APOPTOSE; FAS-L; TRAIL


824/1507US=39 / Câncer
Jagetia G, Krishnan S, Aggarwal BB. Natural agents that can sensitize tumor cells to chemotherapy and radiation therapy. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 211-40. ISBN 978-1-58829-989-5.

SENSIBILIZACAO DE CELULAS TUMORAIS; AGENTES NATURAIS; QUIMIOTERAPIA; TERAPIA POR RADIACAO; QUIMIORRESISTENCIA; RADIORESISTENCIA; POLIFENOIS RADIOSENSIVEIS


825/1507US=39 / Câncer
Johnson DE. Inhibitors of the Bcl-2 protein family as sensitizers to anticancer agents. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 243-61. ISBN 978-1-58829-989-5.

INIBIDORES BCL-2; AGENTES ANTICANCERIGENOS; APOPTOSE; PEPTIDEOS BH3


826/1507US=39 / Câncer
Wilson TR, Longley DB, Johnston PG. Therapeutic targeting of apoptosis in cancer. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 263-78. ISBN 978-1-58829-989-5.

APOPTOSE NO CANCRO; SEGMENTACAO TERAPEUTICA


827/1507US=39 / Câncer
Banerji S, Ande SR, Maddika S, Banerji V, Rashedi I, Owens NW, Zuse A, Schweizer F, Los M. Peptides and peptidomimetics as cancer therapy sensitizing agents. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 279-303. ISBN 978-1-58829-989-5.

PEPTIDOS; PEPTIDOMIMETICOS; AGENTES SENSIBILIZANTES; TERAPIA DO CANCRO


828/1507US=39 / Câncer
Dings RPM, Klein M, Mayo KH. Non-peptidic mimetics as cancer-sensitizing agents. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 305-25. ISBN 978-1-58829-989-5.

AGENTES SENSIBILIZADORES NAO-PEPTIDICOS MIMETICOS; CANCER; TERAPEUTICA DE COMBINACAO


829/1507US=39 / Câncer
Sarkar FH, Li Y. Sensitization of cancer cells to cancer therapies by isoflavone and its synthetic derivatives. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 327-35. ISBN 978-1-58829-989-5.

SENSIBILIZACAO DAS CELULAS CANCEROSAS; TERAPIA DO CANCER; ISOFLAVONA; DERIVADOS SINTETICOS


830/1507US=39 / Câncer
Förster Y, Schwenzer B. Antisense oligonucleotides and siRNA as specific inhibitors of gene expression: mechanisms of action and therapeutic potential. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 337-62. ISBN 978-1-58829-989-5.

OLIGONUCLEOTIDOS ANTI-SENTIDO; SIRNA COMO INIBIDORES ESPECIFICOS; EXPRESSAO DO GENE; MECANISMOS DE ACAO; POTENCIAL TERAPEUTICO


831/1507US=39 / Câncer
Efferth T, Wink M. DNA polymorphisms affecting chemosensitivity toward drugs. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 365-87. ISBN 978-1-58829-989-5.

POLIMORFISMOS DE DNA; QUIMIOSENSIBILIDADE; DEFICIENCIA EM GLICOSE-6-FOSFATO DESIDROGENASE; CANCER


832/1507US=39 / Câncer
Cecchin E, Libra M, Cannavò C, Bruni B, Fulvi A, Toffoli G, Stivala F. Pharmacogenetics in cancer management: scenario for tailored therapy. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 389-403. ISBN 978-1-58829-989-5.

CANCER. TERAPIA; FARMACOGENETICA; METABOLISMO DE FARMACOS; TRANSPORTE DE FARMACOS; MECANISMO DE ACAO DOS FARMACOS


833/1507Câncer
Schiavon BN, Vassallo J, Rocha RM. Is polysomy 17 an important phenomenon to predict treatment with trastuzumab in breast cancer ?. Applied Cancer Research, São Paulo: Tecmedd, v.31, n.4, p. 138-42, 2011. ISSN 1980-5578.

Disponível em: http://accamargo.phlnet.com.br/applied/ACR2011;31p.138-42.pdf

NEOPLASIAS DA MAMA; HER-2; HIBIDIZACAO; POLISOME; TRASTUZUMAB; FLUORESCENCIA


834/1507Câncer
Wainstein AJA, Kansaon MJM, Siqueira RR, Conceição SA, Lacerda LT, Oliveira BRR, Santos FAV. Primary anorectal melanoma: report of 4 cases and literature review (case report). Applied Cancer Research, São Paulo: Tecmedd, v.31, n.4, p. 146-50, 2011. ISSN 1980-5578.

Disponível em: http://accamargo.phlnet.com.br/applied/ACR2011;31p.146-50.pdf

NEOPLASIA DE ANUS; MELANOMA; NEOPLASIA RETAL


835/1507US=42 / Biol/Mol
Sarasin A. Progress and prospects of xeroderma pigmentosum therapy. In: Ahmad SI, Hanaoka F. Molecular mechanisms of xeroderma pigmentosum. New York: Springer, 2008. p. 144-51. (Advances in Experimental Medicine and Biology, 637) ISBN 978-0-387-09598-1.

XERODERMA PIGMENTOSO; TERAPIA


836/1507Câncer
Campanholi LL, Duprat Neto JP, Fregnani JHTG. Analysis of physical therapy in patients who had radical lymphadenectomy for cutaneous melanoma. Applied Cancer Research, São Paulo: Tecmedd, v.32, n.1, p. 12-5, 2012. ISSN 1980-5578.

Disponível em: http://accamargo.phlnet.com.br/applied/ACR2012;32(1)p.12-5.pdf

LINFEDEMA; FISIOTERAPIA; MELANOMA; LINFONODO; REABILITACAO


837/1507US=42 / Gastro
Lankisch PG. Treatment of acute pancreatitis: conservative therapy of acute pancreatitis. In: Beger H, Warshaw A, Büchler M, Kozarek RA, Lerch MM, Neoptolemos JP, Shiratori K, Whitcomb DC, Rau BM. The pancreas: an integrated textbook of basic science, medicine, and surgery. 2nd ed. Massachuetts: Blackwell Scientific Publications, 2008. p. 273-80. ISBN 978-1-4051-4664-7.

PANCREATITE AGUDA. TERAPIA; TERAPIA CONSERVADORA


838/1507US=42 / Gastro
Kozarek RA. Endoscopic and interventional therapy of chronic pancreatitis. In: Beger H, Warshaw A, Büchler M, Kozarek RA, Lerch MM, Neoptolemos JP, Shiratori K, Whitcomb DC, Rau BM. The pancreas: an integrated textbook of basic science, medicine, and surgery. 2nd ed. Massachuetts: Blackwell Scientific Publications, 2008. p. 527-36. ISBN 978-1-4051-4664-7.

PANCREATITE CRONICA; TERAPIA ENDOSCOPICA; TERAPIA DE INTERVENCAO; ICTERICIA OBSTRUTIVA; INTERRUPCOES DUCTAIS


839/1507US=47 / Câncer
Knudsen ES, Braden WA. RB-pathway: cell control and cancer therapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 1-17. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7.

VIA RB; CONTROLE DO CANCER; TERAPIA CELULAR; SUPRESSOR DE TUMOR; RETINOBLASTOMA; CICLINAS; QUIMIOTERAPIA; TERAPIA DE ALVO MOLECULAR; CICLO CELULAR; E2F; ANTIMETABOLITOS; AGENTES ANTIMICROTUBULOS


840/1507US=47 / Câncer
Klein C, Vassilev LT. Targeting the p53/MDM2 pathway for cancer therapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 19-56. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7.

SEGMENTACAO DA VIA P53/MDM2; TERAPIA DE CANCER; PROTEINA P53; MDM2; SUPRESSOR DE TUMOR; INTERACAO PROTEINA-PROTEINA; INTERACAO P53-MDM2


Primeira | Anterior | Próxima | Última